tradingkey.logo

Integra Lifesciences Holdings Corp

IART
查看详细走势图
12.660USD
+0.070+0.56%
收盘 12/24, 13:00美东报价延迟15分钟
985.39M总市值
亏损市盈率 TTM

Integra Lifesciences Holdings Corp

12.660
+0.070+0.56%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.56%

5天

-2.91%

1月

+1.44%

6月

+6.66%

今年开始到现在

-44.18%

1年

-42.79%

查看详细走势图

操作建议

Integra Lifesciences Holdings Corp当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名93/206位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价15.50。中期看,股价处于下降通道。近一个月,市场表现一般,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Integra Lifesciences Holdings Corp评分

相关信息

行业排名
93 / 206
全市场排名
213 / 4562
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 12 位分析师
持有
评级
15.500
目标均价
+19.05%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Integra Lifesciences Holdings Corp亮点

亮点风险
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
业绩转亏
公司业绩转亏,最新年度亏损美元
估值合理
公司最新PE估值-1.96,处于3年历史合理位
机构减仓
最新机构持股73.55M股,环比减少25.42%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值634.00

Integra Lifesciences Holdings Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Integra Lifesciences Holdings Corp简介

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
公司代码IART
公司Integra Lifesciences Holdings Corp
CEOPoul (Mojdeh)
网址https://www.integralife.com/

常见问题

Integra Lifesciences Holdings Corp(IART)的当前股价是多少?

Integra Lifesciences Holdings Corp(IART)的当前股价是 12.660。

Integra Lifesciences Holdings Corp的股票代码是什么?

Integra Lifesciences Holdings Corp的股票代码是IART。

Integra Lifesciences Holdings Corp股票的52周最高点是多少?

Integra Lifesciences Holdings Corp股票的52周最高点是27.130。

Integra Lifesciences Holdings Corp股票的52周最低点是多少?

Integra Lifesciences Holdings Corp股票的52周最低点是10.870。

Integra Lifesciences Holdings Corp的市值是多少?

Integra Lifesciences Holdings Corp的市值是985.39M。

Integra Lifesciences Holdings Corp的净利润是多少?

Integra Lifesciences Holdings Corp的净利润为-6.94M。

现在Integra Lifesciences Holdings Corp(IART)的股票是买入、持有还是卖出?

根据分析师评级,Integra Lifesciences Holdings Corp(IART)的总体评级为持有,目标价格为15.500。

Integra Lifesciences Holdings Corp(IART)股票的每股收益(EPS TTM)是多少

Integra Lifesciences Holdings Corp(IART)股票的每股收益(EPS TTM)是-6.465。
KeyAI